AzTrials
AzTrials

SpondyloarthritisPhase 3SELECT-AXIS 2NCT04169373

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

A Phase 3 study testing Upadacitinib in people with Spondyloarthritis, run by AbbVie at 212 sites in 25 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Spondyloarthritis
What is being tested?
Upadacitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
734 participants
Where
212 sitesin 25 countries
Study dates
26 Nov 2019to 28 Feb 2025
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Study 1:
  • Must have a clinical diagnosis of ankylosing spondylitis (AS) and meet the modified New York Criteria for AS,
  • Must not have total spinal ankylosis
  • Must have been previously exposed to 1 or 2 bDMARDs (at least 1 tumor necrosis factor [TNF] inhibitor or 1 interleukin [IL]-17 inhibitor [IL-17i]), and must have discontinued the bDMARD therapy due to either lack of efficacy (after at least 12 weeks of treatment with a bDMARD at an adequate dose) or intolerance (irrespective of treatment duration). Prior exposure to two bDMARDs was allowed for no more than 30% of patients; among patients with prior exposure to two bDMARDs, a lack of efficacy to one bDMARD and intolerance to another was permitted, but a patient could not have a lack of efficacy to two bDMARDs
  • Study 2:
  • Must have a clinical diagnosis of nr-axSpA fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA but not meeting the radiologic criterion of the modified New York criteria for AS
Show all 11Show fewer
  • Must have objective signs of active inflammation consistent with axSpA on magnetic resonance imaging (MRI) of sacroiliac (SI) joints or based on high sensitivity C-reactive protein (hsCRP) > the upper limit of normal (ULN).
  • Prior treatment with at most one bDMARD (either TNF inhibitor or IL-17i) is allowed for at least 20% but no more than 35% of enrolled patients who had to discontinue the prior bDMARD due to either lack of efficacy (after ≥ 12 weeks at an adequate dose) or intolerance (regardless of treatment duration).
  • Must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at the Screening and Baseline Visits.
  • Must have a Total Back Pain score ≥ 4 based on a 0 - 10 numerical rating scale at the Screening and Baseline Visits.
  • Has had an inadequate response to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or has an intolerance to or contraindication for NSAIDs as defined by the Investigator.

Who cannot join

  • Must not have been exposed to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib [Rinvoq®], tofacitinib [Xeljanz®], baricitinib [Olumiant®], filgotinib, ruxolitinib [Jakafi®], abrocitinib [PF-04965842], and peficitinib [Smyraf®]).
  • Prior bDMARD therapy must be washed out.
  • Participant must not have a history of an allergic reaction or significant sensitivity to constituents of the study drug.

Trial locations and contacts

212 sites in 25 countries.

212 sites in 25 countries

United States41 sites
  • Tekton Research, Inc. /ID# 214923

    Austin, Texas, 78745

  • Arthritis & Rheumatic Disease Specialties /ID# 215306

    Aventura, Florida, 33180

  • Rheumatology and Pulmonary Clinic /ID# 214946

    Beckley, West Virginia, 25801

  • Tufts Medical Center /ID# 215925

    Boston, Massachusetts, 02111-1552

  • Trinity Universal Research Associates - Carrollton /ID# 214948

    Carrollton, Texas, 75007

  • Great Lakes Clinical Trials /ID# 215790

    Chicago, Illinois, 60640

  • Arthritis and Osteoporosis Clinic Of Brazos Valley /ID# 215805

    College Station, Texas, 77845

  • Denver Arthritis Clinic /ID# 215346

    Denver, Colorado, 80230

  • Wayne State University Health Center /ID# 215930

    Detroit, Michigan, 48201-2153

  • Altoona Ctr Clinical Res /ID# 214770

    Duncansville, Pennsylvania, 16635

  • St. Paul Rheumatology /ID# 215537

    Eagan, Minnesota, 55121

  • Arizona Arthritis & Rheumatology Associates, P.C. /ID# 215282

    Flagstaff, Arizona, 86001-6269

  • Tekton Research /ID# 215054

    Fort Collins, Colorado, 80528

  • JPS Rheumatology Clinic /ID# 215962

    Fort Worth, Texas, 76104-4917

  • Klein and Associates MD /ID# 214767

    Hagerstown, Maryland, 21740

  • Sweet Hope Research Specialty Inc /ID# 215931

    Hialeah, Florida, 33016-1897

  • Memorial Rheumatology /ID# 216311

    Houston, Texas, 77024-2420

  • Biopharma Informatic, LLC /ID# 215885

    Houston, Texas, 77043

  • Biopharma Informatic - Park Row /ID# 215907

    Houston, Texas, 77084

  • Newport Huntington Medical Group /ID# 216281

    Huntington Beach, California, 92648-5994

  • Advanced Rheumatology, PC /ID# 214973

    Lansing, Michigan, 48910

  • Cape Fear Arthritis Care /ID# 215927

    Leland, North Carolina, 28451

  • West Texas Clinical Research /ID# 215928

    Lubbock, Texas, 79410-1198

  • Marietta Memorial Hospital /ID# 215929

    Marietta, Ohio, 45750-1635

  • NYU Langone Orthopedic Center /ID# 215594

    New York, New York, 10016-2772

  • Health Research of Oklahoma /ID# 215117

    Oklahoma City, Oklahoma, 73103-2400

  • Innovation Medical Research Center /ID# 216068

    Palmetto Bay, Florida, 33157-1737

  • AZ Arthritis and Rheumotology Research, PLLC /ID# 215113

    Phoenix, Arizona, 85032-9306

  • Trinity Universal Research Associates, Inc /ID# 215189

    Plano, Texas, 75024-5283

  • Oregon Health and Science University /ID# 216446

    Portland, Oregon, 97239

  • St. Lawrence Health System /ID# 215844

    Potsdam, New York, 13676

  • Greater Chicago Specialty Physicians /ID# 216213

    Schaumburg, Illinois, 60195-3106

  • Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055

    Skokie, Illinois, 60076

  • West Virginia Research Inst /ID# 214921

    South Charleston, West Virginia, 25309

  • STAT Research, Inc. /ID# 215264

    Springboro, Ohio, 45066

  • Clinvest Research LLC /ID# 215785

    Springfield, Missouri, 65807

  • CenterPointe Institute of Research /ID# 215793

    St Louis, Missouri, 63128-3841

  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 214731

    Tucson, Arizona, 85704

  • Inland Rheum & Osteo Med Grp /ID# 215807

    Upland, California, 91786

  • Conquest Research /ID# 215804

    Winter Park, Florida, 32789

  • Clinical Pharmacology Study Group /ID# 215293

    Worcester, Massachusetts, 01605

Other trials in United States

Russia19 sites
  • Chelyabinsk Regional Clinical Hospital /ID# 214463

    Chelyabinsk, Chelyabinsk Oblast, 454087

  • Alliance Biomedical Ural Group /ID# 214457

    Izhevsk, Udmurtiya Republic, 426061

  • Immanuel Kant Baltic Federal University /ID# 218259

    Kaliningrad, Kaliningrad Oblast, 236016

  • Kazan State Medical University /ID# 214421

    Kazan', Tatarstan, Respublika, 420012

  • LLC Family Outpatient Clinic № /ID# 214455

    Korolev, Moscow, 141060

  • Research Institute of Rheumatology named after V.A. Nasonova /ID# 214459

    Moscow, Moscow, 115522

  • Olla-Med Clinic /ID# 214460

    Moscow, 105554

  • City Clinical Hospital n.a. O.M. Filatov /ID# 214486

    Moscow, 111539

  • LLC Medical Center /ID# 214410

    Novosibirsk, Novosibirsk Oblast, 630099

  • Omsk Regional Clinic Hospital /ID# 214464

    Omsk, 644111

  • Orenburg State Medical University /ID# 214408

    Orenburg, 460000

  • LLC Novaya Klinika /ID# 214420

    Pyatigorsk, Stavropol Kray, 357500

  • Ryazan State Medical University named after academician I.P. Pavlov /ID# 214418

    Ryazan, 390026

  • Nort-Western State Medical University n.a. Mechnikov /ID# 214454

    Saint Petersburg, Sankt-Peterburg, 193015

  • Clinical Rheumatologic Hospital No 25 /ID# 214488

    Saint Petersburg, 190068

  • RZD-Medicine Saratov /ID# 214465

    Saratov, 410004

  • Ulyanovsk Regional Clinical Hospital /ID# 214458

    Ulyanovsk, 432017

  • Family Clinic /ID# 214737

    Yekaterinburg, Sverdlovsk Oblast, 620109

  • Central City Hospital #7 /ID# 214741

    Yekaterinburg, Sverdlovsk Oblast, 620137

Other trials in Russia

Japan16 sites
  • National Hospital Organization Asahikawa Medical Center /ID# 214930

    Asahikawa-shi, Hokkaido, 070-8644

  • Juntendo University Hospital /ID# 214929

    Bunkyo-ku, Tokyo, 113-8431

  • St.Luke's International Hospital /ID# 215414

    Chuo-ku, Tokyo, 104-8560

  • National Hospital Organization Osaka Minami Medical Center /ID# 214205

    Kawachinagano Shi, Osaka, 586-8521

  • Kobe University Hospital /ID# 214598

    Kobe, Hyōgo, 650-0017

  • Kuwana City Medical Center /ID# 215196

    Kuwana-shi, Mie-ken, 511-0061

  • Matsuyama Red Cross Hospital /ID# 216021

    Matsuyama, Ehime, 790-8524

  • Nagasaki University Hospital /ID# 215947

    Nagasaki, Nagasaki, 852-8501

  • Daido Clinic /ID# 214735

    Nagoya, Aichi-ken, 457-8511

  • Hyogo College of Medicine College Hospital /Id# 215638

    Nishinomiya-shi, Hyōgo, 663-8501

  • Japanese Red Cross Okayama Hospital /ID# 214732

    Okayama, Okayama-ken, 700-8607

  • Kita-harima Medical Center /ID# 216069

    Ono-shi, Hyōgo, 675-1327

  • Osaka City General Hospital /ID# 215640

    Osaka, Osaka, 534-0021

  • Hokkaido University Hospital /ID# 215221

    Sapporo, Hokkaido, 060-8648

  • Sasebo Chuo Hospital /ID# 214703

    Sasebo-shi, Nagasaki, 857-1195

  • Okinawa Prefectural Chubu Hospital /ID# 215575

    Uruma, Okinawa, 904-2293

Other trials in Japan

Ukraine16 sites
  • MNPE Chernihiv Regional Hospital of the Chernihiv Region Council /ID# 214145

    Chernihiv, 14029

  • State Institution L.T. Malaya Therapy National Institute of the NAMS of Ukraine /ID# 214155

    Kharkiv, 61039

  • CNCE of Kharkiv Regional Council Regional Clinical Hospital /ID# 214158

    Kharkiv, 61058

  • MNI City Multidisciplinary Hospital #18 /ID# 214154

    Kharkiv, 61110

  • Khmelnytskyi Regional Hospital /ID# 214153

    Khmelnytskyi, 29000

  • MI Kryvyi Rih City Clinical Hospital No.2 /ID# 214152

    Kryvyi Rih, 50056

  • Medical Center LLC Institute of Rheumatology /ID# 214146

    Kyiv, 02081

  • Kyiv Railway Clinical Hosp No.2 /ID# 214779

    Kyiv, 03049

  • Medical Center CONSILIUM MEDICAL /ID# 216234

    Kyiv, 04050

  • MNI KRC Kyiv Regional Clinical Hospital /ID# 214156

    Kyiv, 04107

  • Municipal Non-Commercial Enterprise Odesa Regional Clinical Hospital of the Od /ID# 214159

    Odesa, 65025

  • Multifield Medical Centre of ONMU /ID# 214149

    Odesa, 65026

  • PI "Poltava Regional Clinical Hospital n.a. M.V.Sklifosovsky" /ID# 214151

    Poltava, 36011

  • Ternopil University Hospital /ID# 214705

    Ternopil, 46002

  • CNE Vinnytsya Regional Clinical Hospital named after N.I.Pirogov /ID# 214147

    Vinnytsia, 21028

  • Clinic of Scientific Research Institute of Invalid Rehabilitation /ID# 214148

    Vinnytsia, 21029

Other trials in Ukraine

China11 sites
  • The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia Universi /ID# 216612

    Baotou, Inner Mongolia, 014016

  • Peking Union Medical College Hospital /ID# 216545

    Beijing, Beijing Municipality, 100730

  • The first affiliated hospital of bengbu medical college /ID# 216609

    Bengbu, Anhui, 233004

  • Guangdong Provincial People's Hospital /ID# 216645

    Guangzhou, Guangdong, 510080

  • Anhui Provincial Hospital /ID# 216631

    Hefei, Anhui, 230001

  • First Affiliated Hospital of Kunming Medical University /ID# 217945

    Kunming, 650032

  • Huashan Hospital, Fudan University /ID# 216646

    Shanghai, Shanghai Municipality, 200040

  • The First Affiliated Hospital of Shantou University Medical College /ID# 217883

    Shantou, Guangdong, 515041

  • Shenzhen People's Hospital /ID# 225438

    Shenzhen, Guangdong, 518020

  • The First Affiliated Hospital of Soochow University /ID# 216607

    Suzhou, Jiangsu, 215006

  • Zhuzhou Central Hospital /ID# 216644

    Zhuzhou, Hunan, 412007

Other trials in China

Czechia11 sites
  • REVMACLINIC s.r.o. /ID# 215153

    Brno, 602 00

  • Revmacentrum MUDr. Mostera, s.r.o. /ID# 215161

    Brno, 615 00

  • Revmatologie, s.r.o. /ID# 215309

    Brno, 638 00

  • CCR Ostrava, s.r.o. /ID# 215226

    Ostrava, 702 00

  • ARTHROHELP, s.r.o. /ID# 215224

    Pardubice, 530 02

  • Revmatologicky ustav v Praze /ID# 215154

    Prague, 128 00

  • PV MEDICAL Services s.r.o. /ID# 215119

    Prague, 130 00

  • Revmatologicka ambulance - MUDr. Zuzana Urbanova /ID# 215652

    Prague, 140 00

  • Thomayerova nemocnice /ID# 215118

    Prague, 140 59

  • Fakultni Nemocnice v Motole /ID# 215160

    Prague, 150 06

  • MEDICAL PLUS, s.r.o. /ID# 215324

    Uherské Hradiště, 686 01

Other trials in Czechia

Germany9 sites
  • Rheumatologische Schwerpunktpraxis Brandt-Juergens /ID# 214282

    Berlin, 12161

  • Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 214211

    Berlin, 12203

  • Rheuma Research Lausitz, Dr. Mario Sutowicz /ID# 214218

    Cottbus, 30342

  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 214207

    Dresden, 01307

  • Universitaetsklinikum Erlangen /ID# 214281

    Erlangen, Bavaria, 91054

  • Praxisgemeinschaft Rheumatologie Nephrologie Erlangen /ID# 214212

    Erlangen, 91056

  • MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH /ID# 214208

    Hamburg, 20095

  • Medizinische Hochschule Hannover /ID# 214209

    Hanover, 30625

  • MVZ für Rheumatologie Dr. M. Welcker GmbH /ID# 214261

    Planegg, 82152

Other trials in Germany

Bulgaria8 sites
  • UMHAT Kaspela EOOD /ID# 214803

    Plovdiv, 4001

  • Medical center Unimed /ID# 214816

    Plovdiv, 4023

  • MHAT Plovdiv /ID# 214815

    Plovdiv, 4027

  • Medical center Teodora /ID# 214813

    Rousse, 7012

  • Medical center Excelsior /ID# 214805

    Sofia, 1407

  • UMHAT Sveti Ivan Rilski /ID# 214804

    Sofia, 1431

  • UMHAT Sveti Ivan Rilski /ID# 214806

    Sofia, 1431

  • Diagnostic consultative center 17 Sofia /ID# 214808

    Sofia, 1505

Other trials in Bulgaria

Hungary8 sites
  • Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 215183

    Budapest, 1023

  • Debreceni Egyetem Klinikai Kozpont /ID# 215187

    Debrecen, Hajdú-Bihar, 4032

  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 215186

    Gyula, 5700

  • Hevizgyogyfurdo es Szent Andras Reumakorhaz /ID# 215184

    Hévíz, 8380

  • Pest Megyei Flor Ferenc Korhaz /ID# 214501

    Kistarcsa, 2143

  • Rehavita Kft HU /ID# 215188

    Kormend, Zala County, 9900

  • CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 215181

    Székesfehérvár, 8000

  • Vital Medical Center Orvosi es Fogaszati Kozpont /ID# 215182

    Veszprém, Veszprém megye, 8200

Other trials in Hungary

Argentina7 sites
  • Organizacion Medica de Investigacion (OMI) /ID# 214557

    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1015

  • Hospital Cordoba /ID# 215846

    Córdoba, 5000

  • Instituto Medico Strusberg /ID# 215239

    Córdoba, 5000

  • Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 214556

    Rosario, Santa Fe Province, 2000

  • Instituto CAICI /ID# 215242

    Rosario, Santa Fe Province, 2000

  • Centro de Investigaciones Medicas Tucuman /ID# 214559

    San Miguel de Tucumán, Tucumán Province, 4000

  • Cimer /Id# 215240

    San Miguel de Tucumán, 4000

Other trials in Argentina

South Korea7 sites
  • Gachon University Gil Medical Center /ID# 214534

    Incheon, 21565

  • Hanyang University Seoul Hospital /ID# 214297

    Seoul, Seoul Teugbyeolsi, 04763

  • Seoul National University Hospital /ID# 214532

    Seoul, 03080

  • Kyunghee University Hospital at Gangdong /ID# 214296

    Seoul, 05278

  • Asan Medical Center /ID# 214294

    Seoul, 05505

  • The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 214295

    Seoul, 06591

  • Ajou University Hospital /ID# 214533

    Suwon, Gyeonggido, 16499

Other trials in South Korea

Spain7 sites
  • Hospital Universitario Reina Sofia /ID# 214968

    Córdoba, 14004

  • Hospital Universitario La Paz /ID# 216032

    Madrid, 28046

  • Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 214967

    Sabadell, Barcelona, 08208

  • Hospital Unversitario Marques de Valdecilla /ID# 214965

    Santander, Cantabria, 39008

  • Hospital Universitario y Politecnico La Fe /ID# 214966

    Valencia, 46026

  • Hospital Meixoeiro (CHUVI) /ID# 214969

    Vigo, Pontevedra, 36213

  • Hospital Marina Baixa /ID# 215970

    Villajoyosa, Alicante, 03570

Other trials in Spain

Poland6 sites
  • Osteo-Medic S.C. /ID# 214351

    Bialystok, Podlaskie Voivodeship, 15-351

  • REUMED Sp.z o.o. Filia nr 1 /ID# 214353

    Lublin, Lublin Voivodeship, 20-607

  • ETYKA-Osrodek Badan Klinicznych /ID# 215572

    Olsztyn, Warmian-Masurian Voivodeship, 10-117

  • AI Centrum Medyczne Sp. z o.o. sp.k. /ID# 214354

    Poznan, Greater Poland Voivodeship, 61-113

  • Nasz Lekarz Przychodnie Medyczne /ID# 214352

    Torun, Kuyavian-Pomeranian Voivodeship, 87-100

  • WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 215093

    Wroclaw, Lower Silesian Voivodeship, 51-685

Other trials in Poland

Australia5 sites
  • Emeritus Research Sydney /ID# 215507

    Botany, New South Wales, 2019

  • Emeritus Research /ID# 215506

    Camberwell, Victoria, 3124

  • Monash Medical Centre /ID# 215509

    Clayton, Victoria, 3168

  • Barwon Rheumatology Services /ID# 215508

    Geelong, Victoria, 3220

  • BJC Health /ID# 215510

    Parramatta, New South Wales, 2150

Other trials in Australia

Brazil5 sites
  • EDUMED Educacao em Saude S/S L /ID# 215111

    Curitiba, Paraná, 80440-080

  • CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 215277

    Juiz de Fora, Minas Gerais, 36010-570

  • LMK Sevicos Medicos S/S /ID# 215112

    Porto Alegre, Rio Grande do Sul, 90480-000

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 215176

    São José do Rio Preto, São Paulo, 15090-000

  • CPCLIN - Centro de Pesquisas Clínicas /ID# 215175

    São Paulo, 01228-200

Other trials in Brazil

Canada5 sites
  • Applied Medical Informatics Research Inc. (AMIR) /ID# 215303

    Montreal, Quebec, H4A 3T2

  • Centre de recherche du CHUQ /ID# 215038

    Québec, G1R 3S2

  • Toronto Western Hospital /ID# 215041

    Toronto, Ontario, M5T 2S8

  • Centre de Recherche Musculo-Squelettique /ID# 215096

    Trois-Rivières, Quebec, G8Z 1Y2

  • Percuro Clinical Research, Ltd /ID# 215302

    Victoria, British Columbia, V8V 3M9

Other trials in Canada

Slovakia5 sites
  • Univerzitna nemocnica Bratislava Nemocnica Stare Mesto /ID# 214675

    Bratislava, 813 69

  • Reum.hapi s.r.o. /ID# 224268

    Nové Mesto nad Váhom, 915 01

  • Narodny ustav reumatickych chorob /ID# 214674

    Piešťany, 921 12

  • MUDr. Zuzana Cizmarikova s.r.o. /ID# 215220

    Poprad, 058 01

  • ALBAMED s.r.o. /ID# 215248

    Zvolen, 960 01

Other trials in Slovakia

Taiwan5 sites
  • Kaohsiung Veterans General Hos /ID# 214332

    Kaohsiung City, Taichung, 81362

  • Far Eastern Memorial Hospital /ID# 215384

    New Taipei City, 22060

  • Chung Shan Medical University Hospital /ID# 214018

    Taichung, 40201

  • China Medical University Hospital /ID# 214019

    Taichung, 40447

  • Cathay General Hospital /ID# 214183

    Taipei, 10630

Other trials in Taiwan

France4 sites
  • CHU Bordeaux - Hopital Pellegrin /ID# 214784

    Bordeaux, 33000

  • Hopital Ambroise Pare /ID# 214783

    Boulogne-Billancourt, 92104

  • AP-HP - Hopital Cochin /ID# 214782

    Paris, 75014

  • CHU Toulouse /ID# 214780

    Toulouse, Occitanie, 31300

Other trials in France

Israel4 sites
  • Bnai Zion Medical Center /ID# 215856

    Haifa, 3339419

  • Meir Medical Center /ID# 217255

    Kfar Saba, 4428164

  • The Chaim Sheba Medical Center /ID# 215854

    Ramat Gan, Tel Aviv, 5265601

  • Tel Aviv Sourasky Medical Center /ID# 216956

    Tel Aviv, Tel Aviv, 6423906

Other trials in Israel

United Kingdom4 sites
  • Doncaster Royal Infirmary /ID# 214971

    Armthorpe Road, DN2 5LT

  • West Suffolk Hospital /ID# 215529

    Bury St Edmunds, Suffolk, IP33 2QZ

  • Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 214865

    Norwich, Norfolk, NR4 7UY

  • Minerva Health Centre /ID# 216226

    Preston, Lancashire, PR1 6SB

Other trials in United Kingdom

Belgium3 sites
  • ReumaClinic /ID# 215005

    Genk, 3600

  • UZ Gent /ID# 215004

    Ghent, Oost-Vlaanderen, 9000

  • Universitair Ziekenhuis Leuven /ID# 215006

    Leuven, Vlaams-Brabant, 3000

Other trials in Belgium

Turkey (Türkiye)3 sites
  • Istanbul University Cerrahpasa Faculty of Medicine /ID# 214895

    Cerrahpaşa, 34098

  • Mugla Sitki Kocman University Medical Faculty /ID# 215358

    Muğla, 48000

  • Hacettepe Universitesi Tip Fak /ID# 214898

    Sihhiye, Ankara, 06100

Other trials in Turkey (Türkiye)

New Zealand2 sites
  • Waikato Hospital /ID# 215503

    Hamilton, Waikato Region, 3240

  • Middlemore Clinical Trials /ID# 215502

    Papatoetoe, Auckland, 2025

Other trials in New Zealand

Mexico1 site
  • CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 215217

    Mexico City, Mexico City, 11850

Other trials in Mexico

About this study

Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.

The main objectives of this protocol are:

  • To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2).
  • To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2).
  • To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2).
  • To evaluate the maintenance of disease control after withdrawal of upadacitinib.
Read the detailed description

Study 1 (bDMARD-IR AS) is comprised of a 14-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 90-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day Follow-Up Visit (F/U Visit).

Study 2 (nr-axSpA) is comprised of a 52-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 52-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day F/U Visit.

In the Double-Blind Period for both studies, participants are randomized in a 1:1 ratio to receive either upadacitinib or placebo once daily (QD).

Participants in the placebo group switch to upadacitinib 15 mg QD at Week 14 in the Open-Label Extension Period for Study 1 (bDMARD-IR AS) and Week 52 in the Open-Label Extension Period for Study 2 (nr-axSpA).

Participants in remission at Week 104 have the option to enroll in a remission-withdrawal period.

Study M19-944 protocol uses a common screening platform for determining eligibility into Study 1 and Study 2. Each study has its own objectives, hypothesis testing, randomization, data collection, and adequate power for primary and secondary endpoints. Analysis and reporting are conducted separately and independently for each study.

Being tested
Upadacitinib, Placebo
Keywords
Upadacitinib, Axial Spondyloarthritis (axSpA), Spondyloarthritis, Ankylosing Spondylitis (AS)
Medical subject headings
Spondylarthritis, Axial Spondyloarthritis, Spondylitis, Ankylosing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UpadacitinibDrug

    Also called ABT-494, RINVOQ

    Upadacitinib tablet administered orally

  • PlaceboDrug

    Placebo for upadacitinib tablet administered orally

Study groups in NCT04169373
Study groupRoleWhat they receive
Study 1: Upadacitinib 15 mgExperimentalParticipants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Receives: Drug: Upadacitinib
Study 1: PlaceboPlacebo comparatorParticipants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Receives: Drug: Upadacitinib; Drug: Placebo
Study 2: Upadacitinib 15 mgExperimentalParticipants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Receives: Drug: Upadacitinib
Study 2: PlaceboPlacebo comparatorParticipants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Receives: Drug: Upadacitinib; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

  2. Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

Secondary outcomes (35)
  1. Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.

    Measured: Baseline and Week 14

  2. Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14

    In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.

    Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.

    The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  3. Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.

    A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

    Measured: Baseline and Week 14

  4. Study 1: Percentage of Participants With an ASAS20 Response at Week 14

    ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:

    • Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

  5. Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.

    Measured: Week 14

  6. Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

    Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

    Measured: Baseline and Week 14

  7. Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

    Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

    Measured: Baseline and Week 14

  8. Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.

    Measured: Week 14

  9. Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14

    The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

    Measured: Baseline and Week 14

  10. Study 1: Percentage of Participants With ASAS Partial Remission at Week 14

    ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Week 14

  11. Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14

    The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).

    Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

    Measured: Baseline and Week 14

  12. Study 1: Change From Baseline in ASAS Health Index at Week 14

    The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  13. Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14

    The BASMI is a composite score based on 5 direct measurements of spinal mobility:

    1. cervical rotation (measured in degrees),
    2. tragus to wall distance (in centimeters [cm])
    3. lumbar side flexion (in cm),
    4. lumbar flexion (modified Schober's) (in cm) and
    5. intermalleolar distance (in cm).

    Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  14. Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14

    The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  15. Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14

    In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.

    Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.

    The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  16. Study 2: Change From Baseline in ASDAS at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.

    Measured: Baseline and Week 14

  17. Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14

    In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.

    Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.

    The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  18. Study 2: Percentage of Participants With BASDAI 50 Response at Week 14

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.

    A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

    Measured: Baseline and Week 14

  19. Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.

    Measured: Week 14

  20. Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

    Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

    Measured: Baseline and Week 14

  21. Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

    Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

    Measured: Baseline and Week 14

  22. Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.

    Measured: Week 14

  23. Study 2: Percentage of Participants With ASAS Partial Remission at Week 14

    ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Week 14

  24. Study 2: Change From Baseline in BASFI at Week 14

    The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

    Measured: Baseline and Week 14

  25. Study 2: Change From Baseline in ASQoL at Week 14

    The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).

    Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

    Measured: Baseline and Week 14

  26. Study 2: Change From Baseline in ASAS Health Index at Week 14

    The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  27. Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14

    ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:

    • Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

  28. Study 2: Change From Baseline in BASMI(Lin) at Week 14

    The BASMI is a composite score based on 5 direct measurements of spinal mobility:

    1. cervical rotation (measured in degrees),
    2. tragus to wall distance (in centimeters [cm])
    3. lumbar side flexion (in cm),
    4. lumbar flexion (modified Schober's) (in cm) and
    5. intermalleolar distance (in cm).

    Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  29. Study 2: Change From Baseline in MASES at Week 14

    The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  30. Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 52

  31. Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14

    In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.

    Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.

    The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  32. Study 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52

    Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.

    Measured: Week 24, Week 32, Week 40, and Week 52

  33. Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.

    Measured: Baseline and Week 52

  34. Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.

    Measured: Week 52

  35. Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.

    Measured: Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2019
  2. Study start26 Nov 2019
  3. Primary completion2 Sep 2021
  4. Study completion28 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
734 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04169373
Sponsor's protocol ID
M19-944
Other IDs
2022-501018-78-00
Acronym
SELECT-AXIS 2
Status last verified
Feb 2025
First submitted
18 Nov 2019
Last updated
24 Feb 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Publications

  • Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13.

    PubMed 41824252
  • Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.

    PubMed 41039829
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.

    PubMed 40875187
  • Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110.

    PubMed 40037923
  • Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Res Ther. 2025 Feb 4;27(1):23. doi: 10.1186/s13075-024-03441-3.

    PubMed 39905436
  • Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025 May;77(5):536-546. doi: 10.1002/art.43069. Epub 2025 Jan 24.

    PubMed 39624020
  • Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024 Nov 12;26(1):197. doi: 10.1186/s13075-024-03412-8.

    PubMed 39533349
  • Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.

    PubMed 38683479
  • Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.

    PubMed 37982966
  • Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D. Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther. 2023 Aug;10(4):887-899. doi: 10.1007/s40744-023-00550-4. Epub 2023 May 16.

    PubMed 37191738
  • Navarro-Compan V, Baraliakos X, Magrey M, Ostor A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis. Rheumatol Ther. 2023 Jun;10(3):679-691. doi: 10.1007/s40744-023-00536-2. Epub 2023 Feb 23.

    PubMed 36820984
  • Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0.

    PubMed 35908570
  • van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4.

    PubMed 35788492

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in